Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01654276 · ClinicalTrials.gov registry record · Phase 4
Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT01654276 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT01654276, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is being done to evaluate whether the medication, febuxostat, can improve the degree of insulin resistance and other features of the metabolic syndrome (high blood pressure, elevated insulin levels, excess body fat around the waist, and/or high cholesterol) by lowering uric acid levels in the blood.
Interventions
- DRUG Febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01654276
The ClinicalTrials.gov registry entry for NCT01654276 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Febuxostat is the first listed.
NCT01654276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01654276 about?
NCT01654276 is a clinical study titled "Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome". This study is being done to evaluate whether the medication, febuxostat, can improve the degree of insulin resistance and other features of the metabolic syndrome (high blood pressure, elevated insulin levels, excess body fat around the waist, and/or high cholesterol) by lowering uric acid levels in...
What is the current status of trial NCT01654276?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2012-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01654276?
The interventions under investigation include: Febuxostat (DRUG).
Who is sponsoring clinical trial NCT01654276?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.